Finding studies
Finding studies
Take this into the appointment.
Saves the questions and what to expect into your notes, next to the visit they belong to.
Lead
Matthew Galsky
With
OUTLINE: This is a multi-center study Patients will be enrolled into one of two parallel cohorts: * Cohort 1: impaired renal function AND poor performance status (cycle length = 28 days). Everolimus 10 mg orally daily * Cohort 2: impaired renal function OR poor performance status (cycle length = 28 days). Everolimus 10 mg orally daily + IV Paclitaxel 80 mg/m2 on D1, 8, 15 Restaging evaluations will be performed after every 2 cycles. Treatment will continue until disease progression or unacceptable toxicity. Karnofsky performance status 60-70% Life Expectancy: Not specified Hematopoietic: * Absolute neutrophil count (ANC) ≥ 1.5 K/mm3 * Hemoglobin (Hgb) ≥ 9 g/dL * Platelets ≥ 100 K/mm3 * INR ≤ 1.5 (Anticoagulants are allowed if target INR ≤ 1.5 on a stable dose of warfarin or on a stable dose of Low molecular weight (LMW) heparin for at least 2 weeks prior to registration for protocol therapy). * Fasting serum cholesterol ≤300 mg/dL OR ≤7.75 mmol/L * Fasting triglycerides ≤ 2.5 x ULN. * Fasting serum glucose \< 1.5 x ULN Hepatic: * Bilirubin ≤ 1.5 x ULN * Aminotransferases (AST and ALT) ≤ 2.5 x ULN (unless liver metastases, then ≤ 5 x ULN) Renal: * Calculated creatinine clearance of \< 60 using the Cockcroft-Gault formula Cardiovascular: * No symptomatic congestive heart failure of New York heart Association Class III or IV. * No unstable angina pectoris, symptomatic congestive heart failure, myocardial infarction within 6 months of start of study drug, serious uncontrolled cardiac arrhythmia or any other clinically significant cardiac disease.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
